Akebia Therapeutics
AKBA
189 hedge funds and large institutions have $1.52B invested in Akebia Therapeutics in 2020 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 77 increasing their positions, 43 reducing their positions, and 13 closing their positions.
765% more call options, than puts
Call options by funds: $26.1M | Put options by funds: $3.02M
262% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 13
115% more capital invested
Capital invested by funds: $703M → $1.52B (+$812M)
79% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 43
22% more funds holding
Funds holding: 155 → 189 (+34)
7.55% more ownership
Funds ownership: 71.45% → 79% (+7.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$57.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$36.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.5M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$26.2M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$14.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.8M |
| 4 |
Millennium Management
New York
|
-$6.52M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.17M |
AKBA Hedge Fund Activity: Q2 2020 in Review
189 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2020, worth a combined $1.52B — up 115% from $703M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new AKBA positions and 13 closed out — a net gain of 34 holders — while 77 added to existing stakes and 43 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $57.4M. The largest seller was Baupost Group, cutting an estimated $26.2M.
- 189 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2020, up from 155 in Q1 2020.
- Funds reported $1.52B of Akebia Therapeutics stock for Q2 2020, up 115% quarter-over-quarter.
- 47 funds opened new Akebia Therapeutics positions in Q2 2020 and 13 closed out, a net change of +34 holders.
- The largest Akebia Therapeutics buyer in Q2 2020 was Wellington Management Group, an estimated $57.4M added.
- The largest Akebia Therapeutics seller in Q2 2020 was Baupost Group, an estimated $26.2M sold.
Based on aggregated 13F filings for Q2 2020.